In this captivating discussion, Bernd Mühlenweg, SVP at Evotec and expert in cell and gene therapy, shares insights on the industry’s challenges and triumphs. He highlights over 130 ongoing trials, the importance of immune shielding, and the evolution of autologous versus allogeneic therapies. Bernd emphasizes the need for regulatory education and addresses manufacturing hurdles. Despite cautious investor sentiment, he sees potential breakthroughs, particularly in regenerative medicine, that could transform patient care and offer durable solutions.
